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Objectives: To evaluate the prognostic potential of native myocardial T1 in cardiac transthyretin 
amyloidosis (ATTR) and compare native T1 with extracellular volume (ECV) in terms of 
diagnostic accuracy and prognosis.  
Background: ATTR amyloidosis is an increasingly recognised cause of heart failure that has an 
overlapping clinical phenotype with hypertrophic cardiomyopathy (HCM). Native T1 mapping 
by CMR is useful for diagnosis in cardiac amyloidosis but its prognostic potential has never been 
assessed.  
Methods: 134 patients with wild-type ATTR (ATTRwt) (122 males, age 76±7 years), 81 
patients with hereditary-type (ATTRm) (60 males, age 69±11 years), 44 patients with HCM (32 
males, age 51±13 years), and 12 asymptomatic mutation carriers (4 males, age 47±10 years) 
were studied. All subjects underwent CMR with T1 mapping and ECV measurement. ATTR 
patients also underwent 99mTc-DPD scintigraphy. 
Results: Native T1 and ECV were elevated in ATTR compared to HCM (p<0.001) and were 
both associated with a high diagnostic accuracy (area under the curve, 0.87(95% confidence 
interval [CI]:0.82–0.91) for T1 and of 0.91 (95%CI:0.87–0.94 for ECV).  No significant 
difference in native T1 and ECV was found between ATTRwt and ATTRm, and ECV correlated 
well with 99mTc-DPD scintigraphy. During follow-up of a mean 32 ± 17 months, 55 ATTRwt 
and 40 ATTRm patients died. Native T1 and ECV predicted death (T1: HR 1.225 each 59ms 
increase; 95% CI:1.010-1.486;p<0.05 and ECV: HR 1.155 each 3% increase; 95% CI:1.097-
1.216;p<0.001), but only ECV remained independently predictive after adjustment for age, N-
terminal pro b-type natriuretic peptide, LV ejection fraction, E/E’, LV mass index and DPD 
grade and LGE.  
Conclusions: Native T1 mapping and ECV are good diagnostic techniques in cardiac ATTR 
amyloidosis that associate with prognosis. Both parameters correlate with mortality, but only 
ECV remains independently predictive of prognosis, suggesting that it is a more robust marker in 
cardiac ATTR amyloidosis. 
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LIST OF ABBREVIATIONS 
ATTR amyloidosis: Transthyretin amyloidosis 
ATTRm: Hereditary transthyretin amyloidosis 
ATTRwt: Wild-type transthyretin amyloidosis 
CMR: Cardiovascular magnetic resonance 
ECV: Extracellular volume fraction 
HCM: Hypertrophic cardiomyopathy 
LGE: Late gadolinium enhancement 
LVH: Left ventricular hypertrophy 
NT-proBNP: N-terminal pro-brain natriuretic peptide 




Systemic amyloidosis is caused by deposition of insoluble amyloid fibrils in the extracellular 
space of tissues and organs, leading to progressive organ failure and death. More than 30 
different precursor proteins have the propensity to form amyloid fibrils (1), but only two types 
account for most cases of cardiac amyloidosis: immunoglobulin light-chain (AL) and 
transthyretin (ATTR). Transthyretin-related amyloidosis, in turn, may be either hereditary 
(ATTRm) arising from misfolding of mutated TTR or non-hereditary, caused by misfolding of 
wild-type transthyretin (ATTRwt, also known as senile systemic amyloidosis). Cardiac 
involvement is the principal driver of prognosis in systemic amyloidosis although outcome 
differs markedly between types (2). 
Cardiac ATTR amyloidosis is a progressive and usually fatal cause of heart failure, typically 
occurring in older people, for which awareness and clinical recognition have greatly increased in 
recent times.  
Formerly, diagnosis of cardiac ATTR amyloidosis required demonstration of amyloid deposits 
with an endomyocardial biopsy (3) but advances in diagnostic imaging, including cardiac 
magnetic resonance (CMR) imaging (4,5) and re-purposed bone scintigraphy (6-9) along with 
blood/urine exclusion of free light chains now enable non-invasive, non-histological diagnosis of 
cardiac ATTR amyloidosis, which has resulted in a greater than 30-fold increase in the diagnosis 
of this condition in our Center during the past decade.(10) 
CMR has lately emerged as a robust technique that can provide unique information about tissue 
composition. CMR can visualize, with late gadolinium enhancement (LGE), and measure, with 
T1 mapping, the continuum of cardiac amyloid deposition. T1 mapping, before the 




myocardial T1), whilst T1 maps pre and post administration of Gadolinium-based contrast can be 
used to calculate the myocardial extracellular volume (ECV). Both native myocardial T1 and 
ECV have been extensively validated in cardiac amyloidosis as surrogate markers of infiltration. 
They have been shown to correlate with disease burden, detect early disease and have good 
diagnostic accuracy (4,11). Furthermore, in cardiac AL amyloidosis, higher T1 and ECV 
measurements have been shown to be associated with a shorter event free survival (12). 
However, in cardiac ATTR amyloidosis, although the prognostic significance of ECV has been 
presented,(13) neither the prognostic potential of native T1, nor the relative diagnostic accuracy 
or ability for native T1 versus ECV to track disease severity have been studied. 
From anecdotal observation and our previous work in AL amyloidosis, we hypothesized that 
native myocardial T1 predicts survival in cardiac ATTR amyloidosis (12) and that there may be 
significant differences between the ability native T1 and ECV to track disease progression.  
METHODS 
Ethical approval was granted by the University College London/University College London 
Hospitals Joint Committees on the Ethics of Human Research Committee, and all participants 
provided written informed consent. 
Study population 
A total of 271 subjects were prospectively recruited between 2011 and 2015. The study 
population underwent comprehensive clinical evaluation at the National Amyloidosis Centre, 
London, and comprised the three groups described below. Patients were systematically followed 
up until June 13, 2017, the date of censoring.  
ATTR amyloidosis patients: Cardiac ATTR amyloidosis was defined as the combination of 
symptoms with an echocardiogram consistent with or suggestive of cardiac amyloidosis, a grade 
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2 or 3 cardiac uptake on 99mTc-DPD scintigraphy in the absence of a monoclonal gammopathy 
or, in the presence of monoclonal gammopathy, a cardiac biopsy confirming ATTR (14). 
Possible cardiac ATTR amyloidosis was defined by grade 1 cardiac uptake on 99mTc-DPD 
scintigraphy in the absence of a monoclonal gammopathy.(4,13)  All subjects underwent 
sequencing of exons 2, 3, and 4 of the TTR gene. 
Of the 271 subjects included in this study, 198 had definitive cardiac ATTR amyloidosis (171 
male, 86%; age 74 ± 8 years), 17 had possible cardiac ATTR amyloidosis (11 male, 65%; age 70 
± 14 years), 12 were TTR gene mutation carriers and 44 had hypertrophic cardiomyopathy. 
TTR gene mutation carriers: Individuals with amyloidogenic TTR gene mutations were defined 
as carriers on the basis of being clinically asymptomatic, having no cardiac uptake on 99mTc-
DPD scintigraphy and normal echocardiography, CMR, N-terminal proB-type natriuretic peptide 
(NT-proBNP) and Troponin T. Twelve TTR gene mutation carriers were recruited (4 male, 33%; 
age 47 ± 11 years). 
HCM patients: There were 44 patients with HCM (32 male, 73%; 51 ± 13 years) fulfilling 
diagnostic criteria. Hypertrophic cardiomyopathy was defined by the presence of increased 
ventricular wall thickness or mass in the absence of loading conditions (hypertension, valve 
disease) sufficient to cause the observed abnormality.(15) In addition to the TTR gene carrier 
group described above, HCM patients constituted the non-cardiac ATTR group.  
Exclusion criteria 





All participants underwent standard CMR on a 1.5T clinical scanner. A standard volumetric and 
LGE study was performed. The gadolinium-based contrast agent used was 0.1 mmol/kg of 
gadoterate meglumine (Dotarem, Guerbet S.A., France). LGE imaging was acquired using 
magnitude reconstruction in all patients and phase-sensitive inversion recovery reconstruction 
(PSIR) in 82% of patients with either standard fast low-angle shot inversion recovery or balanced 
steady state free precession sequence. For native and post-contrast T1 mapping, 4-chamber long-
axis images were acquired using the shortened modified look-locker inversion recovery 
(ShMOLLI) sequence after regional shimming. (16) After a bolus of contrast and standard LGE 
imaging, the T1 measurement was repeated with the ShMOLLI sequence.(17)  
CMR image analysis 
 All CMR images and maps were analysed offline. T1 measurement was performed by drawing a 
region of interest (ROI) in the basal to mid septum of the appropriate 4-chamber map. For ECV 
measurement, a single ROI was drawn in each of the 4 required areas: myocardial T1 estimates 
(basal to mid septum in 4 chamber map) and blood T1 estimates (LV cavity blood pool in 4 
chamber map, avoiding the papillary muscles) before and after contrast administration. 
Hematocrit was measured in all subjects immediately before each CMR study. ECV was 
calculated as: myocardial ECV = (1-hematocrit) x (ΔR1myocardium/ΔR1blood), where 
R1=1/T1. 
Before our adoption of PSIR for all amyloidosis patients, because myocardial nulling can be 
difficult in the presence of amyloid, any confusion with magnitude reconstruction images was 
resolved by selecting the images that most matched the post-contrast T1 maps, with “bright” 
LGE expected to correlate with areas of the lowest postcontrast T1 (i.e., the highest gadolinium 
concentration, the highest interstitial expansion). 
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The LGE pattern was classified into 3 groups according to the degree of transmurality: group 1, 
no LGE; group 2, subendocardial LGE (when there was global subendocardial but no transmural 
LGE); and group 3, transmural LGE (when the LGE was extending transmurally). A scan was 
classified by the most extensive LGE identified. Thus, a patient with basal transmural LGE but 
apical subendocardial LGE would be classified as transmural.(5) 
99mTc-DPD Scintigraphy 
Subjects were scanned using hybrid single-photon emission computed tomography (SPECT) 
computed tomography (CT) gamma cameras following administration of 700 MBq of 
intravenously-injected 99mTc-DPD. Whole-body planar images were acquired after 3 h, followed 
by SPECT of the heart coupled with a low-dose, noncontrast CT scan.(18) Gated and nongated 
cardiac SPECT reconstruction and SPECT-CT image fusion was performed on the Xeleris 
workstation (GE Healthcare, Wauwatosa, Wisconsin). Cardiac retention of 99mTc-DPD was 
scored visually according to the grading devised by Perugini et al. (6) using the following 
grading system: grade 0, absent cardiac uptake; grade 1, mild cardiac uptake less than bone; 
grade 2, moderate cardiac uptake equal or greater than bone; and grade 3, intense cardiac uptake 
associated with substantial reduction or loss of bone signal. Uptake was verified by visual review 
of SPECT imaging. 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM, Armonk, New 
York). All continuous variables were normally distributed (Shapiro-Wilk test), other than NT-
proBNP, which was natural log transformed for bivariate testing. These are presented as mean ± 
SD with untransformed NT-proBNP presented as median and interquartile range. Comparisons 
between multiple groups were performed by 1-way analysis of variance with post hoc Bonferroni 
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correction. The chi-square test or Fisher exact test was used to compare categorical data as 
appropriate. Correlations between parameters were assessed using Pearson (r) or Spearman’s 
rho. Receiver-operating characteristic (ROC) curve analysis was performed to define the 
diagnostic accuracy of native T1 and ECV. The AUCs were compared statistically for correlated 
ROC curves with DeLong method.  
Survival was evaluated using Cox proportional hazards regression analysis, providing estimated 
hazard ratios (HR) with 95% confidence intervals (CI) and Kaplan-Meier curves. All variables 
were first explored with univariate Cox regression. Separate multivariate models evaluated the 
independent predictive value of T1 and ECV above other clinically and statistically significant 
covariates. Statistical significance was defined as p < 0.05. 
RESULTS 
The details of the 271 subjects are shown in table 1. A total of 198 patients with definitive ATTR 
amyloidosis, 17 patients with possible ATTR amyloidosis and 12 mutation carriers were 
enrolled. These subjects were compared with 44 patients with HCM. 
Of the patients with definitive ATTR, 125 had wild-type ATTR and 73 hereditary ATTR 
(ATTRm); the TTR mutations were V122I (n = 40); T60A (n = 20); V30M (n = 5); and S77Y, 
E54G, E54L, E89K, D38Y, F44L, G89L and L12P in one case each. Among 17 patients with 
suspected cardiac ATTR (DPD grade 1 one DPD scintigraphy), 9 had wild-type TTR gene 
sequence and 8 had amyloidogenic TTR gene mutations comprising S77Y (n = 3) and V30M, 
I107F, E54G, G47V, and I84S in 1 case each. The variants present in mutation carriers were 
T60A (n = 6); V30M (n = 5); and S77Y (n = 1). 
Correlation between T1 and ECV  
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Native T1 and ECV have a good correlation (R = 0.726) in all ATTR subjects and this 
correlation remained good in low ECV values (R = 0.735 in ECV< 0.40). However, this 
correlation was significantly worse when high ECV values were analysed (R = 0.351 in ECV ≥ 
0.40). (Figure 1 and 2) Native T1 and ECV have also a good correlation in HCM patients 
(R=0.684). 
T1 and ECV diagnostic accuracy 
As predicted, T1 and ECV were elevated in ATTR patients compared with HCM and mutation 
carriers (native T1: 1096 ± 51ms vs 1013 ± 64ms, p<0.001; ECV: 0.61 ± 0.12 vs 0.36 ± 0.13, 
p<0.001). 
The ROC curve analysis was performed for the discrimination of definitive cardiac ATTR 
amyloidosis or possible cardiac ATTR amyloidosis from the combined differential diagnoses of 
HCM or ATTR mutation carriers without evidence of cardiac amyloidosis. 
The combined group of definitive ATTR and possible ATTR patients had an area under the ROC 
curve (AUC) of 0.87 (95% confidence interval [CI]: 0.82 – 0.91) for T1 and 0.91 (95% 
confidence interval [CI]: 0.87 – 0.94) for ECV. The T1 cut-off value to diagnose definitive or 
possible cardiac ATTR was 1048ms with a specificity of 80.36% and sensitivity of 86.54% and 
for ECV was 0.469 with a specificity of 82.14% and sensitivity of 92.46% 
When a subgroup analysis was performed according the ATTR aetiology (ATTRm, ATTRwt) 
diagnostic accuracy remained similarly good. The AUC for T1 in ATTRm was 0.88 (95% 
confidence interval [CI]: 0.82 – 0.93) compared with an AUC for ECV of 0.92 (95% confidence 
interval [CI]: 0.87 – 0.96). T1 and ECV had also similar diagnostic accuracy in ATTRwt 
patients:  T1 AUC was 0.86 (95% confidence interval [CI]: 0.80 – 0.90) and ECV AUC of 0.90 
(95% confidence interval [CI]: 0.85 – 0.94). (Figure 3) The T1 cut-off value to diagnose 
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definitive or possible cardiac ATTRm was 1051ms with a specificity of 82.14% and sensitivity 
of 86.08% and 0.469 for ECV with a specificity of 82.14% and sensitivity of 91.89%. The T1 
cut-off value to diagnose definitive or possible cardiac ATTRwt was 1048ms with a specificity 
of 80.36% and sensitivity of 86.05% and 0.469 for ECV with a specificity of 82.14% and 
sensitivity of 92.80%. 
There were no statistically significant differences in the AUC for native T1 and ECV in all 
subgroup comparisons.  
T1, ECV and DPD/LGE findings, cardiac function, biomarkers and 6-min walk test 
Both native T1 and ECV increased with increasing cardiac uptake as assessed by bone 
scintigraphy (p < 0.001 for trend). Native T1 and ECV were not elevated in mutation carriers 
(native T1: 968 ± 41ms; ECV 0.29 ± 0.03) but were elevated in the 17 patients with possible 
ATTR (DPD grade 1) (native T1: 1023 ± 64ms, ECV: 0.41 ± 0.13, p < 0.05 for both), all of 
which had no amyloid-like LGE by CMR, with the exception of patients with the Se77Tyr 
variant. (Figure 4) 
Native T1 and ECV values were also elevated in HCM patients compared to ATTR mutation 
carriers (native T1 1026 ± 64ms, ECV 0.38 ± 0.15, p<0.05 for both). 
Correlations were broadly similar for T1 and ECV across ATTR types (table 2), but ECV 
correlated more strongly with parameters of cardiac function, biomarkers and 6 minute walking 
test than T1. Overall in all ATTR patients, T1 and ECV correlated with indexes of systolic and 
diastolic function, indexed LV mass, and known prognostic biomarkers as well as functional 
markers (6-minute walk test performance) in keeping with our previous findings (4,11,12). 
Furthermore, ECV correlated with indexed stroke volume but T1 did not.  
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For subgroup analyses (ATTRm and ATTRwt), correlations were lower, reflecting the smaller 
sample sizes.   
In asymptomatic ATTR mutations carriers, there were no statistically significant correlations. 
Association between T1, ECV and outcome 
At follow-up (mean 32 ± 17 months), 95 of 227 (42%) subjects had died (55 with wild-type 
ATTR and 40 with ATTRm). Native T1 and ECV predicted death in the ATTR population (T1: 
HR 1.225 each 59ms increase; 95% confidence interval, 1.010-1.486; p<0.05 and ECV: HR, 
1.155 each 3% increase; 95% confidence interval, 1.097-1.216; p<0.001), and ECV also 
predicted death separately in the wild-type ATTR and ATTRm groups (p<0.01 for both). 
However, native T1 was not predictive of death when wild-type ATTR and ATTRm groups were 
analysed separately. (Figure 5)  
ECV remained significantly associated with mortality (HR: 1.101; 95% CI: 1.022 to 1.187; p < 
0.05) in multivariate Cox models that included age, NT-proBNP, LV ejection fraction, E/E’, LV 
mass index and DPD grade. Only age, ECV and NTproBNP remained significantly associated 
with mortality when LGE was added to the multivariate model (ECV, HR: 1.106 each 3% 
increase; 95% CI: 1.011-1.209; p < 0.05; LGE, HR 0.868; 95% CI: 0.447-1.973; p=0.939). In 
contrast, native T1 didn’t remain significantly associated with mortality after adjustment for age, 
NT-proBNP, LV ejection fraction, E/E’, LV mass index and DPD grade (p=0.971). Native T1 
remained not significant after the addition of LGE to the model (p = 0.729). 
DISCUSSION 
In this large ATTR amyloidosis population, we describe for the first time that native T1 mapping 
and ECV are good diagnostic techniques in cardiac ATTR amyloidosis, however in high levels 
of infiltration, native T1 and ECV can be discordant. Both parameters also correlate with 
12 
 
mortality in cardiac ATTR amyloidosis. Nevertheless, only ECV remains independently 
predictive of prognosis, suggesting that it is a more robust marker in cardiac ATTR amyloidosis. 
(Supplement table 1 and 2) In addition, we demonstrate that non-diagnostic DPD uptake (grade 
1), previously held to be indeterminate but inconsistent with definitive ATTR amyloidosis, is 
associated with abnormal myocardial T1 and ECV, suggesting that CMR can detect a phenotype 
of early amyloid infiltration. 
Native T1 and ECV have lately emerged as the first non-invasive quantitative markers of 
myocardial amyloid infiltration. Our earlier work in ATTR amyloidosis demonstrated that 
elevated native myocardial T1 in cardiac ATTR amyloidosis, was more sensitive than LGE 
imaging and had high diagnostic accuracy. Similarly, ECV was also elevated in patients with 
early stage disease when conventional clinical testing and LGE were normal, it tracked a range 
of markers of disease severity and correlated with prognosis in ATTR amyloidosis.(13) Whilst 
initial studies suggested the two biomarkers had similar clinical implications, important 
differences have recently emerged between the two main types of cardiac amyloidosis, with 
native T1 being relatively higher in AL amyloidosis compared to ATTR, and vice versa for 
ECV.(19) The present study extends these intriguing observations, demonstrating that native T1 
correlated with prognosis in ATTR amyloidosis and highlighting differences between the two 
biomarkers in ATTR amyloidosis, where both native T1 and ECV show a similar diagnostic 
accuracy, but ECV has significantly better correlation with all markers of amyloid burden and 
better prognostic power than native T1. We also demonstrate a good correlation between ECV 
and native T1 for low level of infiltration but very poor correlation when amyloid burden is 
moderate or severe.  
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We believe that these differences represent different biological information provided by native 
T1 and ECV measurements. Cardiac amyloidosis is emerging as a spectrum characterized by 
variable degrees of amyloid infiltration, myocardial edema, inflammation and differential 
myocyte response with myocyte hypertrophy. The administration of contrast and ECV 
measurements enables us to isolate the signal from the extracellular space, but native myocardial 
T1 provides a composite signal from the intra and extracellular spaces, a signal potentially 
influenced by other pathophysiological mechanisms beyond simple amyloid load. Native 
myocardial T1 is highly influenced by water content in the tissue and will therefore be 
significantly raised by the presence of myocardial edema.(20) There are two types of myocardial 
edema: intracellular and extracellular. ECV is elevated when there is extracellular edema and T1 
is elevated in both types.(21) Myocardial edema therefore influences both native T1 and ECV, 
however this influence is disproportionate when the edema is mainly intracellular, with the 
degree of elevation being higher in native T1 than in ECV. On the other hand, a relative increase 
in myocyte hypertrophy compared to amyloid burden will likely decrease the native T1.  
In cardiac ATTR amyloidosis, progressive amyloid deposition is thought to be the main driver of 
disease progression, whilst in AL amyloidosis light chain toxicity or rate of amyloid deposition 
are believed to also play an important role, especially in contributing to early mortality. In this 
context, the better correlation of ECV not only with markers of disease severity but also 
prognosis in ATTR amyloidosis is not surprising, but in keeping with the hypothesis of ECV 
being a better marker of amyloid deposition. This hypothesis is also in line with the different 
significance of native T1 in AL amyloidosis as a powerful independent predictor of prognosis, 
since the ability to track both amyloid load and associated myocardial edema is important in this 
particular amyloid subtype.  
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From this study, different roles emerge for measurements of native T1 and ECV in ATTR 
amyloidosis. The similar diagnostic performance supports the use of native T1 for diagnosis of 
ATTR amyloidosis, which also has the significant advantage of being a non-contrast technique. 
Lack of requirement for contrast means that native myocardial T1 mapping can be performed in 
patients with advanced renal failure, in whom administration of contrast is contraindicated. 
However, in this study we excluded patients with severe renal impairment leaving a knowledge 
gap on the clinical utility on non-contrast CMR in this setting.  Lack of need to give contrast is 
also attractive in the general population given reduced cost and recent potential concerns about 
gadolinium accumulating in the brain, even though this has not been demonstrated for the cyclic 
gadolinium agents, such as that used in this study.(22) On the other hand, ECV is a better marker 
in ATTR amyloidosis for risk stratification and probably for tracking disease progression. These 
differences are also supported and at least in part explained by the relationship between native 
T1 and ECV. There is a good correlation between native T1 and ECV up to and ECV of 0.4, but 
when the extracellular volume expansion is higher the correlation between the two measurements 
becomes poor. The inability of native T1 to track increasing amyloid burden when the ECV is 
greater than 0.4 is likely to represent the main reason for the worse prognostic performance on 
native myocardial T1 compared to ECV. Both biomarkers do increase in subclinical disease, 
supporting their equivalent role as diagnostic markers, as confirmed by similar AUCs in the 
ROC curve analysis.  
Study limitations. Cardiac biopsy was available in only a minority of patients, but this cohort of 
patients was fully characterized using the validated and now widely used non-invasive criteria 
for ATTR. (14) Patients with pacemakers or defibrillators were also excluded. A wide range of 
TTR mutations were included in the analysis. In this study, T1 measurements were performed by 
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drawing a ROI in the basal to mid septum of the appropriate 4-chamber map and the same 
approach was used for ECV measurements, therefore the total extent of cardiac amyloid 
infiltration was not assessed. T2 maps were not acquired in this study, limiting the possibility of 
exploring the hypothesis of myocardial edema as a potential mechanism for the increase in T1.  
Finally, this was a single center study where one T1 mapping technique was used. Care must be 
taken with interpretation of the different T1 cut-offs as T1 varies with magnetic field strength, 
different sequences and thus establishment of normal ranges for a given system, with use of 
standardization tools, is recommended.   
CONCLUSION 
CMR-determined native myocardial T1 and ECV provide excellent diagnostic accuracy for 
identification of ATTR cardiac amyloidosis and both variables track cardiac uptake on DPD 
scintigraphy well. Native T1 and ECV predict survival in ATTR amyloidosis, however ECV is a 
more robust predictor. ECV, a non-invasive quantification of the cardiac amyloid burden, 
remained an independent predictor of prognosis after adjustment for known prognostic factors 






Competency in Medical Knowledge: Native myocardial T1 and ECV have similar diagnostic 
accuracy identifying ATTR amyloidosis and both correlate with mortality. However, ECV is a 
more robust prognostic predictor, remaining independent predictor of prognosis after adjustment 
for knowing prognostic factor.  
Translational outlook: Future studies in cardiac amyloidosis by CMR with T2 mapping could 
help to identify differences in amyloid biology in the main two types of cardiac amyloidosis (AL 
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Figure 1. Correlation between native T1 and ECV in ATTR amyloidosis. Correlation 
between native T1 and ECV, ECV < 0.40 (blue) and ECV ≥ 0.40 (red). 
Figure 2. Native T1, LGE and ECV in ATTR amyloidosis. Short axis SSFP cine (right panel); 
corresponding native T1 maps, PSIR LGE and ECV maps of three subjects; showing (top panel) 
normal T1, transmural LGE, and very elevated ECV values in cardiac ATTR amyloidosis, 
(middle panel) very high T1 values, transmural LGE and high ECV values in another cardiac 
ATTR amyloidosis; and (bottom panel) normal T1, no LGE and normal ECV in a normal heart. 
Both patients (top and middle panel) have high ECV and transmural LGE but discordant T1 




Figure 3. Receiver operative characteristic curve (ROC) for discrimination of possible or 
definite cardiac amyloid by native T1 and ECV from the combined HCM or ATTR 
mutation carriers. ROC curve for discrimination of possible or definite cardiac amyloid by 
native myocardial T1 (blue) and ECV (green) from the clinically significant combined 
differential diagnosis of HCM or ATTR mutation carriers without evidence of cardiac amyloid 
for: (A) all ATTR amyloid patients; (B) hereditary-type ATTR amyloid; or (C) wild-type ATTR. 
AUC= area under the curve; CI = confidence interval. 
 
Figure 4. DPD grade vs native T1 and ECV. DPD grade vs mean native myocardial T1 (left 
panel) and ECV (right panel) ± 2 SE in gene carriers and ATTR patients according to different 








Figure 5. Kaplan-Meier curves for ECV and native T1. Native T1 (top panel) was correlated 
with mortality in all patients with cardiac transthyretin amyloidosis (ATTR) (left panel), but it 
was not correlated with mortality when the analysis was performed in hereditary and wild-type 
ATTR (middle and right panels). ECV (bottom panel) was correlated with mortality in all 
patients with cardiac transthyretin amyloidosis (ATTR) (left panel), as well as in hereditary and 






Table 1. Biomarkers, echocardiographic parameters and CMR findings in patients with ATTR 






(n = 227) 
 
ATTRwt 
(n = 134) 
 
ATTRm 




(n = 12) 
Age, years 72  11 76  7 69  10 47  11  
Biomarkers  
NT-proBNP, ng/L 286 (142 – 538)  322 (179 – 
518) 
258 (126 – 
614) 
6 (3 – 8) 
6 min WT 318  143 313  134 290  142 521  49 
Echocardiographic Parameters  
IVS, cm 1.59  0.28 1.64  0.24 1.61  0.25 0.95  0.12 
LA area, cm2 25.65  6.57 26.66  6.05 25.46  6.31 15.10  5.35 
E-wave, cm/s 0.83  0.20 0.84  0.19 0.82  0.21 0.79  0.12 
A-wave, cm/s 0.49  0.24 0.48  0.24 0.48  0.23 0.67  0.17 
E/A 3.14  8.71 3.16  6.48 3.50  12.12 1.23  0.25 
Average E’, cm/s 0.11  0.78 0.06  0.02 0.20  1.30 0.1  0.05 
E/E’ 16  7 16  6 17  7 13  18 
E-wave deceleration time, ms 178  54 179  55 177  54 181  48 
2D GLS -11.7  4.9 -11.4  4.5 -11.3  5.0  -18.8  3.4 
CMR parameters  
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LV mass, g 241  77 255  72 238  72 114  37 
LV massi, g/cm
2 129  41 134  37 132  40 59  12 
Maximal IVS, mm 19  5 20  4 19  4 9  2 
LVEDV, mL 134  36 137  37 130  35 124  25 
LVEDVi, mL/m
2 71  18 71  19 71  17 66  13 
LVESV, mL 62  31 63  32 64  30 39 12 
LVESVi, mL/m
2 32  16 32  16 35  16 20  6  
LVSV, mL 72  20 74  20 67  21 85  16  
LVSVi, mL/m
2 38  10 38  10 37  10 45  8  
LVEF, % 56  14 56  14 53  15 69  5  
RVEDV, mL 132  38 134  37 130  42 125  27 
RVEDVi, mL/m
2 70  19 70  19 71  20 68  14 
RVESV, mL 63  31 64  31 65  34 43  11 
RVESVi, mL/m
2 34  16 34  16 35  18 23  6 
RVSV, mL 68  20 70  19 63  19 82  17 
RVSVi, mL/m
2 36  10 36  10 34  9 44  9 
RVEF, % 53  13 54  13 51  14 66  4 
LA area, cm2 31  9 33  11 30  6 22  4  
RA area, cm2 28  8 30  8 28  8 19  2  
MAPSE, mm 8  3 8  3 7  3 14  2 






11/23/66 6/25/69 5/24/71 100/0/0 
ECV, % 56  16 60  11 63  13 29  3 
Native Myocardial T1, ms 1079 64 1092  51 1104  49 968  41  
 
Values are mean  SD, %, or median (interquartile range). ATTR = transthyretin amyloidosis; 
CMR = cardiac magnetic resonance; ECV = extracellular volume; GLS = global longitudinal 
strain; IVS = interventricular septum; LA = left atrium; LPW = left posterior wall; LV = left 
ventricular; LVEDD = left ventricular end-diastolic diameter; LVEDV = left ventricular end-
diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end 
systolic volume; LVSV = left ventricular stroke volume; MAPSE = mitral annular plane systolic 
excursion; NT-proBNP = N-terminal pro-B-type natriuretic peptide; RA = right atrium; RVEDV 
= right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; RVESV = 
right ventricular end-systolic volume; RVSV = right ventricular stroke volume; TAPSE = 





Table 2. Correlations between T1 and ECV and Cardiac Function, Biomarkers and 6-minute 
walk test in ATTR patients.  








 T1 ECV T1 ECV T1 ECV T1 ECV 
CMR parameters   
LV massi, g/m
2 0.537* 0.619* 0.356* 0.504* 0.483* 0.535* -0.188 -0.428 
LA areai, cm
2/m2  0.244* 0.403* -0.004 0.267† 0.179† 0.319* -0.159 0.222 
LVEF, % -0.273* -0.567* -0.015 -0.625* -0.301* -0.466* 0.550 0.479 
SVi, ml/m
2 -0.115 -0.402* 0.247† -0.460* -0.184† -0.304* -0.198 -0.076 
Echocardiographic parameters 
E/E’ 0.277* 0.306* 0.238† 0.324* 0.241* 0.313* 0.540 0.679† 
E-wave deceleration 
time, ms 
-0.006 -0.149† -0.077 -0.260† 0.072 -0.112 -0.402 -0.158 
2-dimensional GLS, 
% 
-0.461* -0.671* -0.397* -0.699* -0.374* -0.574* 0.355 0.147 
6 minute walk test 
6-minute walk test, m -0.246* -0.341* -0.051 -0.051 -0.071 -0.233† 0.271 0.235 
Biomarkers       
NT-proBNP, pmol/l 0.482* 0.731* 0.210 0.648* 0.338* 0.597* -0.184 -0.038 
Troponin T, pmol/l 0.462* 0.618* 0.022 0.340† 0.200 0.458* 0.326 -0.179 
Values are Pearson’s r correlation coefficient. *p< 0.01 †p<0.05  
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GLS = global longitudinal strain; LV= left ventricle; LVEF = left ventricular ejection fraction 
NT-proBNP = N-terminal pro-brain natriuretic peptide; SVi = stroke volume indexed. 
 
 
 
 
 
 
 
